SLGC Stock Overview
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Standard BioTools Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.10 |
| 52 Week High | US$3.79 |
| 52 Week Low | US$1.73 |
| Beta | 1.64 |
| 11 Month Change | -13.93% |
| 3 Month Change | 14.13% |
| 1 Year Change | -28.08% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | n/a |
Recent News & Updates
Recent updates
Why Investors Shouldn't Be Surprised By SomaLogic, Inc.'s (NASDAQ:SLGC) P/S
Dec 19
SomaLogic, Inc. (NASDAQ:SLGC) Just Reported, And Analysts Assigned A US$3.93 Price Target
Nov 10SomaLogic, Inc. (NASDAQ:SLGC) Stocks Shoot Up 33% But Its P/S Still Looks Reasonable
Apr 17Downgrade: Here's How Analysts See SomaLogic, Inc. (NASDAQ:SLGC) Performing In The Near Term
Apr 02SomaLogic appoints former Foundation Medicine chief as executive chair
Oct 17SomaLogic acquires Palamedrix to develop next-generation SomaScan Assay
Jul 26We're Hopeful That SomaLogic (NASDAQ:SLGC) Will Use Its Cash Wisely
Jun 06SomaLogic Inc: A Biopharmaceutical Company With An Excellent Upside
Apr 12Calculating The Intrinsic Value Of SomaLogic, Inc. (NASDAQ:SLGC)
Mar 09We Think SomaLogic (NASDAQ:SLGC) Can Easily Afford To Drive Business Growth
Dec 28SomaLogic: The Highest Number Of Proteins Analyzable In A Single Blood Sample In Proteomics
Oct 14Shareholder Returns
| SLGC | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -14.3% | 3.9% | 1.6% |
| 1Y | -28.1% | 4.7% | 32.3% |
Return vs Industry: SLGC underperformed the US Life Sciences industry which returned -2.7% over the past year.
Return vs Market: SLGC underperformed the US Market which returned 21% over the past year.
Price Volatility
| SLGC volatility | |
|---|---|
| SLGC Average Weekly Movement | 11.4% |
| Life Sciences Industry Average Movement | 8.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SLGC's share price has been volatile over the past 3 months.
Volatility Over Time: SLGC's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 451 | Adam Taich | www.somalogic.com |
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company’s SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development.
Standard BioTools Inc. Fundamentals Summary
| SLGC fundamental statistics | |
|---|---|
| Market cap | US$396.23m |
| Earnings (TTM) | -US$130.38m |
| Revenue (TTM) | US$81.72m |
4.8x
P/S Ratio-3.0x
P/E RatioIs SLGC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SLGC income statement (TTM) | |
|---|---|
| Revenue | US$81.72m |
| Cost of Revenue | US$97.89m |
| Gross Profit | -US$16.16m |
| Other Expenses | US$114.22m |
| Earnings | -US$130.38m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.69 |
| Gross Margin | -19.78% |
| Net Profit Margin | -159.54% |
| Debt/Equity Ratio | 0% |
How did SLGC perform over the long term?
See historical performance and comparison